These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33854618)

  • 21. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
    Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
    J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.
    Andina N; Didichenko S; Schmidt-Mende J; Dahinden CA; Simon HU
    J Allergy Clin Immunol; 2009 Mar; 123(3):603-11. PubMed ID: 19152965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells.
    Cervantes-Gomez F; Lavergne B; Keating MJ; Wierda WG; Gandhi V
    Leuk Lymphoma; 2016 Feb; 57(2):436-444. PubMed ID: 26088877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of PIM2 in allergic asthma.
    Du W; Chen T; Ni Y; Hou X; Yu Y; Zhou Q; Wu F; Tang W; Shi G
    Mol Med Rep; 2017 Nov; 16(5):7504-7512. PubMed ID: 28944837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.
    Gómez-Abad C; Pisonero H; Blanco-Aparicio C; Roncador G; González-Menchén A; Martinez-Climent JA; Mata E; Rodríguez ME; Muñoz-González G; Sánchez-Beato M; Leal JF; Bischoff JR; Piris MA
    Blood; 2011 Nov; 118(20):5517-27. PubMed ID: 21937691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.
    Whillock AL; Mambetsariev N; Lin WW; Stunz LL; Bishop GA
    Sci Rep; 2019 Sep; 9(1):12884. PubMed ID: 31501481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of low doses of Tat-PIM2 protein against hippocampal neuronal cell survival.
    Woo SJ; Shin MJ; Kim DW; Jo HS; In Yong J; Ryu EJ; Cha HJ; Kim SJ; Yeo HJ; Cho SB; Park JH; Lee CH; Yeo EJ; Choi YJ; Park S; Im SK; Kim DS; Kwon OS; Park J; Eum WS; Choi SY
    J Neurol Sci; 2015 Nov; 358(1-2):226-35. PubMed ID: 26365288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using insights into Pim1 structure to design new anticancer drugs.
    Schenone S; Tintori C; Botta M
    Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
    Bullock AN; Russo S; Amos A; Pagano N; Bregman H; Debreczeni JE; Lee WH; von Delft F; Meggers E; Knapp S
    PLoS One; 2009 Oct; 4(10):e7112. PubMed ID: 19841674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens.
    Aguirre E; Renner O; Narlik-Grassow M; Blanco-Aparicio C
    Front Oncol; 2014; 4():109. PubMed ID: 24860787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
    Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
    Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
    Takami M; Katayama K; Noguchi K; Sugimoto Y
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1364-1371. PubMed ID: 30017192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1-α signaling pathway.
    Liu Z; Tian M; Ding K; Liu H; Wang Y; Fu R
    Oncol Lett; 2019 Jun; 17(6):5395-5402. PubMed ID: 31186757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
    Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
    J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PIM family of serine/threonine kinases in cancer.
    Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.
    Yang T; Ren C; Qiao P; Han X; Wang L; Lv S; Sun Y; Liu Z; Du Y; Yu Z
    Oncogene; 2018 Nov; 37(45):5997-6009. PubMed ID: 29985480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells.
    Ma L; Pak ML; Ou J; Yu J; St Louis P; Shan Y; Hutchinson L; Li S; Brehm MA; Zhu LJ; Green MR
    Proc Natl Acad Sci U S A; 2019 May; 116(21):10482-10487. PubMed ID: 31068472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.
    Kuang X; Xiong J; Wang W; Li X; Lu T; Fang Q; Wang J
    Life Sci; 2019 Feb; 219():248-256. PubMed ID: 30658101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.